These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24030723)

  • 1. Case-crossover study design in pharmacoepidemiology: systematic review and recommendations.
    Consiglio GP; Burden AM; Maclure M; McCarthy L; Cadarette SM
    Pharmacoepidemiol Drug Saf; 2013 Nov; 22(11):1146-53. PubMed ID: 24030723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the use of methods to mitigate bias from non-transient medications in the case-crossover design: A systematic review.
    Huang HC; Li WC; Tadrous M; Schumock GT; Touchette D; Awadalla S; Lee TA
    Pharmacoepidemiol Drug Saf; 2023 Sep; 32(9):939-950. PubMed ID: 37283212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations.
    Jandoc R; Burden AM; Mamdani M; Lévesque LE; Cadarette SM
    J Clin Epidemiol; 2015 Aug; 68(8):950-6. PubMed ID: 25890805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making.
    Etminan M; Gill S; Fitzgerald M; Samii A
    J Clin Pharmacol; 2006 Jan; 46(1):6-9. PubMed ID: 16397278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case-only designs in pharmacoepidemiology: a systematic review.
    Nordmann S; Biard L; Ravaud P; Esposito-Farèse M; Tubach F
    PLoS One; 2012; 7(11):e49444. PubMed ID: 23166668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-controlled designs in pharmacoepidemiology involving electronic healthcare databases: a systematic review.
    Gault N; Castañeda-Sanabria J; De Rycke Y; Guillo S; Foulon S; Tubach F
    BMC Med Res Methodol; 2017 Feb; 17(1):25. PubMed ID: 28178924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology.
    Cadarette SM; Maclure M; Delaney JAC; Whitaker HJ; Hayes KN; Wang SV; Tadrous M; Gagne JJ; Consiglio GP; Hallas J
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):671-684. PubMed ID: 33715267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoepidemiology I: a review of pharmacoepidemiologic study designs.
    Etminan M; Samii A
    Pharmacotherapy; 2004 Aug; 24(8):964-9. PubMed ID: 15338844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engaging stakeholders in pharmacoepidemiology research: Current state and recommendations.
    Camelo Castillo W; Heath N; Kim J; Yang K; Ritchey ME; dosReis S; Santanello N; West SL
    Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):766-776. PubMed ID: 31050092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Underuse of self-controlled designs in pharmacoepidemiology in electronic healthcare databases: a systematic review.
    Gault N; Castañeda-Sanabria J; Guillo S; Foulon S; Tubach F
    Pharmacoepidemiol Drug Saf; 2016 Apr; 25(4):372-7. PubMed ID: 26781227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The case-crossover study design in pharmacoepidemiology.
    Delaney JA; Suissa S
    Stat Methods Med Res; 2009 Feb; 18(1):53-65. PubMed ID: 18765504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods to control for unmeasured confounding in pharmacoepidemiology: an overview.
    Uddin MJ; Groenwold RH; Ali MS; de Boer A; Roes KC; Chowdhury MA; Klungel OH
    Int J Clin Pharm; 2016 Jun; 38(3):714-23. PubMed ID: 27091131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probabilistic bias analysis in pharmacoepidemiology and comparative effectiveness research: a systematic review.
    Hunnicutt JN; Ulbricht CM; Chrysanthopoulou SA; Lapane KL
    Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1343-1353. PubMed ID: 27593968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice.
    Weldeselassie YG; Whitaker HJ; Farrington CP
    Epidemiol Infect; 2011 Dec; 139(12):1805-17. PubMed ID: 21849099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The case-crossover and case-time-control designs in pharmacoepidemiology.
    Donnan PT; Wang J
    Pharmacoepidemiol Drug Saf; 2001 May; 10(3):259-62. PubMed ID: 11501340
    [No Abstract]   [Full Text] [Related]  

  • 16. Bias in case-crossover studies of medications due to persistent use: A simulation study.
    Bykov K; Wang SV; Hallas J; Pottegård A; Maclure M; Gagne JJ
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1079-1085. PubMed ID: 32548875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoepidemiological safety studies in children: a systematic review.
    Osokogu OU; Dukanovic J; Ferrajolo C; Dodd C; Pacurariu AC; Bramer WM; 'tJong G; Weibel D; Sturkenboom MC; Kaguelidou F
    Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):861-70. PubMed ID: 27255559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of the application of spatial analysis in pharmacoepidemiologic research.
    Dijkstra A; Hak E; Janssen F
    Ann Epidemiol; 2013 Aug; 23(8):504-14. PubMed ID: 23830932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of marginal structural models in pharmacoepidemiologic studies: a systematic review.
    Yang S; Eaton CB; Lu J; Lapane KL
    Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):560-71. PubMed ID: 24458364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Developing process of guide on methodological standards in pharmacoepidemiology (T/CPHARMA 002-2019)].
    Xu Y; Ding CY; Zhuo L; Zhan SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Oct; 40(10):1186-1190. PubMed ID: 31658514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.